Page last updated: 2024-08-21

hesperidin and Dyslipidemias

hesperidin has been researched along with Dyslipidemias in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (50.00)	24.3611
2020's	2 (50.00)	2.80

Authors

Authors	Studies
Caimari, A; Crescenti, A; Del Bas, JM; Domenech-Coca, C; Escoté, X; Mas-Capdevila, A; Teichenne, J	1
Rabbani, N; Thornalley, PJ; Weickert, MO; Xue, M	1
Chen, K; Chen, X; He, Q; Li, X; Liu, Y; Ma, J; Si, M; Sun, C; Wu, H; Yan, Y; Yang, B; Zhu, D	1
Assini, JM; Huff, MW; Mulvihill, EE	1

Reviews

2 review(s) available for hesperidin and Dyslipidemias

Article	Year
Effect of Hesperidin on Cardiovascular Disease Risk Factors: The Role of Intestinal Microbiota on Hesperidin Bioavailability. Nutrients, 2020, May-20, Volume: 12, Issue:5 Topics: Animals; Anti-Inflammatory Agents; Atherosclerosis; Biological Availability; Cardiovascular Diseases; Cardiovascular System; Citrus; Dysbiosis; Dyslipidemias; Flavanones; Gastrointestinal Microbiome; Hesperidin; Humans; Obesity; Risk Factors	2020
Citrus flavonoids and lipid metabolism. Current opinion in lipidology, 2013, Volume: 24, Issue:1 Topics: Animals; Anti-Inflammatory Agents; Atherosclerosis; Citrus; Dyslipidemias; Flavanones; Flavones; Hesperidin; Humans; Hypolipidemic Agents; Inflammation; Lipid Metabolism; Oxidation-Reduction; Phytotherapy	2013

Article

Year

Effect of Hesperidin on Cardiovascular Disease Risk Factors: The Role of Intestinal Microbiota on Hesperidin Bioavailability.

Nutrients, 2020, May-20, Volume: 12, Issue:5

Topics: Animals; Anti-Inflammatory Agents; Atherosclerosis; Biological Availability; Cardiovascular Diseases; Cardiovascular System; Citrus; Dysbiosis; Dyslipidemias; Flavanones; Gastrointestinal Microbiome; Hesperidin; Humans; Obesity; Risk Factors

2020

Citrus flavonoids and lipid metabolism.

Current opinion in lipidology, 2013, Volume: 24, Issue:1

Topics: Animals; Anti-Inflammatory Agents; Atherosclerosis; Citrus; Dyslipidemias; Flavanones; Flavones; Hesperidin; Humans; Hypolipidemic Agents; Inflammation; Lipid Metabolism; Oxidation-Reduction; Phytotherapy

2013

Trials

1 trial(s) available for hesperidin and Dyslipidemias

Article	Year
Reversal of Insulin Resistance in Overweight and Obese Subjects by Nutrients, 2021, Jul-11, Volume: 13, Issue:7 Topics: Adult; Blood Pressure; Body Mass Index; Carrier Proteins; Correlation of Data; Cross-Over Studies; Dietary Supplements; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Glucose Metabolism Disorders; Glycosylation; Hesperidin; Humans; Inflammation; Inflammation Mediators; Insulin Resistance; Leukocytes, Mononuclear; Male; Obesity; Overweight; Pyruvaldehyde; Resveratrol; Tumor Necrosis Factor-alpha	2021

Article

Year

Reversal of Insulin Resistance in Overweight and Obese Subjects by

Nutrients, 2021, Jul-11, Volume: 13, Issue:7

Topics: Adult; Blood Pressure; Body Mass Index; Carrier Proteins; Correlation of Data; Cross-Over Studies; Dietary Supplements; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Glucose Metabolism Disorders; Glycosylation; Hesperidin; Humans; Inflammation; Inflammation Mediators; Insulin Resistance; Leukocytes, Mononuclear; Male; Obesity; Overweight; Pyruvaldehyde; Resveratrol; Tumor Necrosis Factor-alpha

2021

Other Studies

1 other study(ies) available for hesperidin and Dyslipidemias

Article	Year
Neohesperidin Exerts Lipid-Regulating Effects in vitro and in vivo via Fibroblast Growth Factor 21 and AMP-Activated Protein Kinase/Sirtuin Type 1/Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1α Signaling Axis. Pharmacology, 2017, Volume: 100, Issue:3-4 Topics: AMP-Activated Protein Kinases; Animals; Body Weight; Dyslipidemias; Fibroblast Growth Factors; Hep G2 Cells; Hesperidin; Humans; Lipid Metabolism; Liver; Mice, Inbred C57BL; Obesity; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; RNA, Small Interfering; Sirtuin 1	2017

Article

Year

Neohesperidin Exerts Lipid-Regulating Effects in vitro and in vivo via Fibroblast Growth Factor 21 and AMP-Activated Protein Kinase/Sirtuin Type 1/Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1α Signaling Axis.

Pharmacology, 2017, Volume: 100, Issue:3-4

Topics: AMP-Activated Protein Kinases; Animals; Body Weight; Dyslipidemias; Fibroblast Growth Factors; Hep G2 Cells; Hesperidin; Humans; Lipid Metabolism; Liver; Mice, Inbred C57BL; Obesity; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; RNA, Small Interfering; Sirtuin 1

2017